JP2025507923A - ヒトがんの処置における経口ｐｃｌｘ－００１ - Google Patents

ヒトがんの処置における経口ｐｃｌｘ－００１ Download PDF

Info

Publication number
JP2025507923A
JP2025507923A JP2024552265A JP2024552265A JP2025507923A JP 2025507923 A JP2025507923 A JP 2025507923A JP 2024552265 A JP2024552265 A JP 2024552265A JP 2024552265 A JP2024552265 A JP 2024552265A JP 2025507923 A JP2025507923 A JP 2025507923A
Authority
JP
Japan
Prior art keywords
pclx
cancer
hours
per day
oral dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507923A5 (https=
Inventor
ジョン・ロバート・マッキー
ニール・メイナード・デイヴィス
Original Assignee
パシレックス・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パシレックス・ファーマシューティカルズ・インコーポレイテッド filed Critical パシレックス・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2025507923A publication Critical patent/JP2025507923A/ja
Publication of JP2025507923A5 publication Critical patent/JP2025507923A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024552265A 2022-03-03 2023-03-03 ヒトがんの処置における経口ｐｃｌｘ－００１ Pending JP2025507923A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263316153P 2022-03-03 2022-03-03
US63/316,153 2022-03-03
PCT/CA2023/050281 WO2023164776A1 (en) 2022-03-03 2023-03-03 Oral pclx-001 in the treatment of human cancer

Publications (2)

Publication Number Publication Date
JP2025507923A true JP2025507923A (ja) 2025-03-21
JP2025507923A5 JP2025507923A5 (https=) 2026-03-12

Family

ID=87882761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552265A Pending JP2025507923A (ja) 2022-03-03 2023-03-03 ヒトがんの処置における経口ｐｃｌｘ－００１

Country Status (10)

Country Link
US (1) US20250161299A1 (https=)
EP (1) EP4486344A4 (https=)
JP (1) JP2025507923A (https=)
KR (1) KR20240155234A (https=)
CN (1) CN118829428A (https=)
AU (1) AU2023228703A1 (https=)
CA (1) CA3244234A1 (https=)
IL (1) IL314984A (https=)
MX (1) MX2024010584A (https=)
WO (1) WO2023164776A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025050208A1 (en) * 2023-09-05 2025-03-13 Pacylex Pharmaceuticals Inc. Oral pclx-001 in the treatment of human cancer
CN120361006A (zh) * 2025-05-19 2025-07-25 上海交通大学医学院附属第九人民医院 Nmt1抑制剂及其在制备实体瘤治疗药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110974967B (zh) * 2012-10-30 2023-11-07 厄尔莱克斯制药公司 合成致死与癌症的治疗
JP7539760B2 (ja) * 2015-07-17 2024-08-26 パシレックス・ファーマシューティカルズ・インコーポレイテッド Ｎｍｔ２の後成的なサイレンシング
GB201820660D0 (en) * 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
MX2023004341A (es) * 2020-10-20 2023-05-24 Pacylex Pharmaceuticals Inc Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios.

Also Published As

Publication number Publication date
CN118829428A (zh) 2024-10-22
WO2023164776A1 (en) 2023-09-07
MX2024010584A (es) 2024-09-06
KR20240155234A (ko) 2024-10-28
AU2023228703A1 (en) 2024-09-12
CA3244234A1 (en) 2023-09-07
EP4486344A4 (en) 2026-03-04
IL314984A (en) 2024-10-01
EP4486344A1 (en) 2025-01-08
US20250161299A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
JP7493521B2 (ja) Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ
JP2023175811A (ja) 類上皮細胞腫瘍を処置する方法
JP6911047B2 (ja) がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
WO2017013160A1 (en) 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
JP2025507923A (ja) ヒトがんの処置における経口ｐｃｌｘ－００１
EP3405203A1 (en) Methods for treating cancer
CN112587666A (zh) 用于治疗癌症的pd-1/pd-l1相互作用的小分子抑制剂和抗pd-1抗体的组合
WO2018229134A1 (en) Tinostamustine for use in treating ovarian cancer
US20230119759A1 (en) Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
CN114831988A (zh) 治疗非小细胞肺癌的喹啉衍生物
BR112021011699A2 (pt) Terapia de combinação com um inibidor de raf e um inibidor de cdk4/6 para uso no tratamento contra câncer
US20220087946A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
US20170202847A1 (en) Methods for the treatment of tumors
AU2022320615B2 (en) 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
WO2025050208A1 (en) Oral pclx-001 in the treatment of human cancer
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
CA3170021A1 (en) Use of pyrido[1,2-a]pyrimidinone compound in treating lymphoma
AU2022343745B2 (en) Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors
Singh et al. Innovative Targeting Strategies in Breast Cancer Therapy
RU2813111C2 (ru) Фармацевтическая комбинация, содержащая tno155 и рибоциклиб
WO2025188928A1 (en) Administration of low-dose thiostrepton for treating cancer
TW202444376A (zh) 治療癌症之方法
WO2022271939A1 (en) Erk1/2 and cdk4/6 inhibitors combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260303

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260303